Triple Negative Breast Cancer, "I Won't Back Down!": TNBC Day 2017

What is TNBC

WHAT IS TRIPLE NEGATIVE BREAST CANCER?

Just in recent years, Triple Negative Breast Cancer (TNBC) has sparked interest in the news where instead of calling the tumor as ER-negative, PR-negative, and HER2-negative; researchers began using the shorthand term, "Triple Negative," dubbed the "new type" of breast cancer. Being Triple Negative, you don't have a targeted therapy and your only treatment option is chemotherapy.

Triple Negative Breast Cancer is seen in about 15% of all breast cancers. TNBC is a very aggressive cancer that tends to strike younger women, pre-menopause, especially among African-American women and women who have BRCA1 mutations. The tumor tends to be fast growing and is less likely to show up on an annual mammogram. TNBC is more likely to metastasis early on; has a high rate of recurrence in the first 2-3 years from diagnosis and has a poorer prognosis than other types of breast cancer due to lack of specific, targeted treatment for TNBC.

Thursday, March 2, 2017

TNBC Day 2017

Working with Dr. Iman Mohamed and Jan Tipton of University of Toledo Dana Cancer Center to bring our annual Triple Negative Breast Cancer, A Different Shade of Pink educational event held on March 1, 2017 in honor of TNBC Awareness Day.

genetics counselor, Colette Gaba

Know your risk...

Consider genetics if diagnosed with TNBC before the age 60...

TNBC may be associated with inherited mutations

TNBC Survivors

TNBC supporters

Dr. Iman Mohamed explains TNBC is a heterogenous group of
tumors with an absence of Her2, ER and PR that can be further
divided into different subtypes.